The Global Blood Brain Barrier Market is driven by rising prevalence of neurological disorders
The blood-brain barrier (BBB) is a highly selective semipermeable border that separates the circulating blood from the brain and extracellular fluid in the central nervous system. It allows the passage of oxygen, carbon dioxide and nutrients that are important for metabolic processes of the central nervous system while restricting the entry of toxic substances, bacteria and viruses. The BBB plays a crucial role in maintaining normal neural function; however, in pathological conditions like tumors, infections, inflammatory disorders and brain ischemia, it becomes leaky allowing molecules to enter the brain that are otherwise excluded. This disruption in barrier function can significantly affect neural activity and cause cellular damage.
The Global Blood Brain Barrier Market is estimated to be valued at USD 36.2 Mn in 2024 and is expected to reach USD 597.4 Mn by 2031, growing at a compound annual growth rate (CAGR) of 49.3% from 2024 to 2031.
Key players operating in the blood brain barrier market are Abbott Laboratories, Bristol Myers Squibb, F. Hoffman La Roche, Eli Lilly and Company, Johnson and Johnson.
The Global Blood Brain Barrier Market growing prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, meningitis and brain tumors is fueling the demand for effective diagnostics and treatment options. Rapid advances in biotechnology and neuroscience research have paved way for development of targeted drugs that can cross the blood-brain barrier.
Get more insights on - Global Blood Brain Barrier Market
Get this Report in Japanese Language: 世界の血液脳関門市場
Get this Report in Korean Language: 세계의 혈액뇌장벽 시장
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian